Drugs / HER-2/neu intracellular domain protein
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00343109 | Mar 2004 → Jun 2015 | HER2 positive breast carcinoma, male breast carcinoma | University of Washington | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HER-2/neu intracellular domain protein | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00343109 ↗ |
| Modality | Vaccine | “peptide-based vaccine” NCT00343109 ↗ |